Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE stock logo
BNTX
BioNTech
$104.92
-0.5%
$100.58
$76.53
$131.49
$25.22B1.29942,558 shs1.52 million shs
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$128.21
+0.2%
$99.05
$73.04
$128.50
$8.28B0.841.18 million shs4.65 million shs
Beigene, Ltd. stock logo
ONC
Beigene
$276.53
+5.4%
$240.18
$141.31
$287.88
$32.74B0.3451,591 shs724,269 shs
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
$20.16
+3.0%
$23.61
$6.78
$36.91
$14.97B-1.063.62 million shs3.64 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE stock logo
BNTX
BioNTech
-0.51%-4.75%+11.03%+5.48%+7.16%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
+0.20%+0.24%+28.98%+43.12%+20.79%
Beigene, Ltd. stock logo
ONC
Beigene
+5.38%+7.60%+23.05%+6.69%+27,652,999,900.00%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
+2.96%+2.18%-18.08%-3.03%+144.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioNTech SE stock logo
BNTX
BioNTech
2.878 of 5 stars
4.43.00.00.02.50.80.0
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.1757 of 5 stars
2.22.00.00.02.60.80.6
Beigene, Ltd. stock logo
ONC
Beigene
1.3529 of 5 stars
2.50.00.00.02.21.70.6
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
2.9198 of 5 stars
4.43.00.00.02.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE stock logo
BNTX
BioNTech
2.83
Moderate Buy$138.2531.76% Upside
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.32
Hold$129.350.89% Upside
Beigene, Ltd. stock logo
ONC
Beigene
3.00
Buy$319.0015.36% Upside
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
2.77
Moderate Buy$35.0974.06% Upside

Current Analyst Ratings Breakdown

Latest BPMC, ONC, BNTX, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
6/11/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$12.00
6/5/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$134.00 ➝ $145.00
6/5/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.00
6/5/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.00
6/4/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00
6/3/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$132.00
6/3/2025
BioNTech SE stock logo
BNTX
BioNTech
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$151.00 ➝ $155.00
6/3/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE stock logo
BNTX
BioNTech
$2.75B9.18$4.51 per share23.25$92.17 per share1.14
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$562.12M14.73N/AN/A$4.67 per share27.45
Beigene, Ltd. stock logo
ONC
Beigene
$4.18B7.84N/AN/A$37.10 per share7.45
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
$700K21,388.78N/AN/A$0.11 per share183.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE stock logo
BNTX
BioNTech
$1.01B-$3.40N/AN/AN/A-15.16%-2.35%-2.05%8/4/2025 (Estimated)
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A197.25N/A-13.19%-77.49%-20.84%7/30/2025 (Estimated)
Beigene, Ltd. stock logo
ONC
Beigene
-$881.71M-$3.72N/A389.487.73-25.94%-25.12%-14.95%N/A
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%8/5/2025 (Estimated)

Latest BPMC, ONC, BNTX, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Beigene, Ltd. stock logo
ONC
Beigene
-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion
5/1/2025Q1 2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
5/1/2025Q1 2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
-$0.10-$0.09+$0.01-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE stock logo
BNTX
BioNTech
$1.531.46%N/AN/A N/A
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Beigene, Ltd. stock logo
ONC
Beigene
N/AN/AN/AN/AN/A
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE stock logo
BNTX
BioNTech
0.01
7.33
7.21
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.15
2.85
2.80
Beigene, Ltd. stock logo
ONC
Beigene
0.05
1.93
1.72
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
N/A
8.31
8.31

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE stock logo
BNTX
BioNTech
15.52%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/A
Beigene, Ltd. stock logo
ONC
Beigene
48.55%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
BioNTech SE stock logo
BNTX
BioNTech
19.20%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
4.21%
Beigene, Ltd. stock logo
ONC
Beigene
6.62%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
84.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,080240.39 million193.71 millionOptionable
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
64064.58 million61.22 millionOptionable
Beigene, Ltd. stock logo
ONC
Beigene
9,000118.38 million90.59 millionN/A
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
110742.67 million86.28 millionOptionable

Recent News About These Companies

These 24 Stocks Are Ripe for a Short Squeeze
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Leerink Partners
Research Analysts Issue Forecasts for SMMT FY2026 Earnings
Why Summit Therapeutics Stock Tanked Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$104.92 -0.54 (-0.51%)
Closing price 06/12/2025 04:00 PM Eastern
Extended Trading
$106.18 +1.26 (+1.20%)
As of 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$128.21 +0.26 (+0.20%)
Closing price 06/12/2025 04:00 PM Eastern
Extended Trading
$127.97 -0.24 (-0.19%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Beigene stock logo

Beigene NASDAQ:ONC

$276.53 +14.12 (+5.38%)
As of 06/12/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$20.16 +0.58 (+2.96%)
Closing price 06/12/2025 04:00 PM Eastern
Extended Trading
$19.76 -0.40 (-1.98%)
As of 08:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.